Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

To join this study, you must be 18 years or older and have a confirmed diagnosis of advanced or metastatic cancer. This means your cancer has spread beyond its original site.

You should also be generally well enough to take part in the study, meaning you can do most of your daily activities. You'll need to provide a small sample of your cancer tissue for analysis and have at least one measurable tumour that hasn't been treated with radiation recently (though there are special rules for prostate cancer). Your blood counts and organ functions also need to be within a healthy range.

There are also important rules about contraception for both men and women to prevent pregnancy during the study. You simply need to be able to understand and sign the consent forms. People who have other serious health conditions that could make taking part unsafe, or who have recently had another type of cancer (unless it was completely removed), may not be able to join.

If you decide to take part, you'll first have a screening visit to check if the study is right for you. This will involve physical examinations, blood tests, and scans. You'll regularly visit the hospital or clinic for your study medication, which might be Dato-DXd on its own or with other anti-cancer drugs. These visits will also include repeat tests like blood tests and scans to see how you're responding to the treatment and to check for any side effects.

The exact number of visits, tests, and the length of your participation will depend on the specific cancer type you have and how your body responds to the treatment. The study team will explain your specific schedule in detail. There will also be follow-up appointments after your treatment period to monitor your health.